[Obesity, CKD and gender on the 30-day in-hospital mortality risk in adults with COVID-19]

Background: The coronavirus disease 2019 (COVID-19) pandemic is a serious health problem. The Mexican adult population has a high prevalence of obesity and chronic diseases that increase the risk of dying from this disease. Objective: To identify comorbidities predicting the risk of mortality at 30 days in hospitalized adult subjects with positive laboratory COVID-19 test and to evaluate the interaction between chronic diseases and gender. Material and methods: A retrospective cohort study was conducted in 2020, in a western region of the Mexican Pacific. Data from 51,135 hospitalized patients with positive COVID-19 test were analyzed and were retrieved from a normative system for the epidemiological surveillance of viral respiratory diseases (SINOLAVE, according to its initials in Spanish). Death within the first 30 days from hospital admission was the main outcome and risk ratios (RR) with 95% confidence intervals (95% CI) were calculated. Results: The overall mortality rate was 49.6% and most of the comorbidities analyzed were associated with a higher risk of death. There were significant interactions between gender and obesity (p = 0.003) and chronic kidney disease (p = 0.019). The effect of obesity on the risk of a fatal outcome varied by gender: female, RR = 1.04 (95% CI 1.03-1.07);male, RR = 1.07 (95% CI: 1.06-1.09). Conclusions: A high mortality was observed among the hospitalized patients analyzed and statistically significant factors associated with their risk were identified (gender, obesity, and kidney disease).

HIGHER COVID-19 POSITIVITY and LOWER VACCINATIONS among PEOPLE WHO USE DRUGS

Background: The COVID-19 pandemic has disproportionately impacted people who use illicit drugs and misuse prescription drugs (PWUD), including increased risk for infection with SARS-CoV-2, clinical COVID-19, and poorer health outcomes. The reasons for this disparity are multifactorial and may include numerous social and structural factors. Yet, little is known about COVID-19 testing and vaccinations among PWUD. Methods: This cross-sectional study was conducted in Miami, Florida, USA between March and September 2021 with the support of the National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) initiative. Participants had to be 18 years of age and older and willing to be tested for COVID-19. Recruitment included convenience and snowball sampling. The RADx-UP survey (available at https://radx-up.org/) was administered via telephone. Results: A total of 931 participants were enrolled in the study;median age was 59 (53, 64) years, 65.5% were Black, 32.1% Hispanic, and 69.2% had a household income of less than $15,000 in 2019. Nearly a third of participants (32.6%) used drugs. Additionally, 37.6% smoked cigarettes, and 5.2% consumed alcohol for four or more days per week. Twenty percent of participants had never been tested for COVID-19. Of those who reported ever being tested, 14.1% reported ever being positive for SARS-CoV-2, with 67.2% of those having moderate-to-severe symptoms and 26.7% reporting being hospitalized due to COVID-19. Overall, 19 (2.2%) participants tested positive for SARS-CoV-2 at the time of the study, which was more frequent among PWUD than drug non-users (4.2% vs. 1.2%, respectively;p=0.004). PWUD, compared to drug non-users, were less likely to be vaccinated against COVID-19 (66.7% vs. 75.2% for any one dose, respectively;p=0.006). Compared to drug non-users, PWUD had 3.62 (95% CI: 1.41, 9.30;p=0.008) times higher odds of being positive for SARS-CoV-2 based on rt-PCR testing at the time of interview, and 0.66 (95% CI: 0.49, 0.89;p=0.006) times lower odds of being at least partially vaccinated against COVID-19. Conclusion: People who use drugs may be at increased risk of contracting SARS-CoV-2 and developing COVID-19, which could be in part related to lower vaccination rates in addition to comorbidities and lifestyle factors. Testing and immunization plans are needed that are specific for PWUD, considering the barriers and facilitators of this population.

Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection.

OBJECTIVE: The aim of the study was to evaluate factors predicting severe symptomatic laboratory-confirmed (via Reverse transcription polymerase chain reaction, RT-PCR polymerase chain reaction) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection. STUDY DESIGN: This is a nationwide retrospective cohort study that was conducted in Mexico. METHODS: Data from 258 reinfection cases (at least 28 days between both episodes onset) were analyzed. We used risk ratios (RRs) and 95% confidence intervals (CIs) to evaluate predictors of severe (dyspnea requiring hospital admission) secondary SARS-CoV-2 infection. RESULTS: The risk of severe disease was 14.7%, and the observed overall fatality rate was 4.3%. Patients with more serious primary disease were more likely to develop severe symptoms (39.5% vs. 5.5%, P < 0.001) during reinfection. In multiple analysis, factors associated with an increased risk of severe symptomatic SARS-CoV-2 reinfection were increasing age (RRper year = 1.007, 95% CI = 1.003-1.010), comorbidities (namely, obesity [RR = 1.12, 95% CI = 1.01-1.24], asthma [RR = 1.26, 95% CI = 1.06-1.50], type 2 diabetes mellitus [RR = 1.22, 95% CI = 1.07-1.38]), and previous severe laboratory-confirmed coronavirus disease 2019 (RR = 1.20, 95% CI = 1.03-1.39). CONCLUSIONS: To the best of our knowledge, this is the first study evaluating disease outcomes in a large set of laboratory-positive cases of symptomatic SARS-CoV-2 reinfection, and factors associated with illness severity were characterized. Our results may contribute to the current knowledge of SARS-CoV-2 pathogenicity and to identify populations at increased risk of a poorer outcome after reinfection.

Predictors of laboratory-positive COVID-19 in children and teenagers.

OBJECTIVE: The aim of the study was to identify factors predicting laboratory-positive coronavirus disease 2019 (COVID-19) in pediatric patients with acute respiratory symptoms. STUDY DESIGN: We conducted a cross-sectional analysis of a prospective cohort study. METHODS: Data from 1849 individuals were analyzed. COVID-19 was confirmed (reverse transcription-quantitative polymerase chain reaction) in 15.9% of patients, and factors predicting a positive test result were evaluated through prevalence odds ratios and 95% confidence intervals. RESULTS: Increasing age, personal history of obesity, and household contact with a case were found to be associated, in the multiple regression model, with increased odds of a positive test result. Young patients residing in areas with higher population sizes, as well as those with severe respiratory symptoms, were less likely to be laboratory confirmed. CONCLUSIONS: Early identification and isolation of children and teenagers with suggestive symptoms of COVID-19 is important to limit viral spread. We identified several factors predicting the laboratory test result. Our findings are relevant from a public health policy perspective, particularly after the restart of in-person academic activities.